Dextrothyroxine

Dextrothyroxine
Systematic (IUPAC) name
	(2R)-2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoic acid
Clinical data
Trade names	Choloxin
AHFS/Drugs.com	Multum Consumer Information
Pregnancy; category	US: B (No risk in non-human studies); ;
Legal status	Discontinued;
Identifiers
CAS Number	51-49-0
ATC code	C10AX01 (WHO)
PubChem	CID: 8730
DrugBank	DB00509
ChemSpider	8402
UNII	4W9K63FION
ChEBI	CHEBI:30659
ChEMBL	CHEMBL559
Synonyms	D-3,5,3',5'-tetraiodothyronine
Chemical data
Formula	C15H11I4NO4
Molecular mass	776.87 g/mol
	SMILES O=C(O)[C@H](N)Cc2cc(I)c(Oc1cc(I)c(O)c(I)c1)c(I)c2 ;
	InChI InChI=1S/C15H11I4NO4/c16-8-4-7(5-9(17)13(8)21)24-14-10(18)1-6(2-11(14)19)3-12(20)15(22)23/h1-2,4-5,12,21H,3,20H2,(H,22,23)/t12-/m1/s1 ; Key:XUIIKFGFIJCVMT-GFCCVEGCSA-N ;

Dextrothyroxine (trade name Choloxin) saw research as a cholesterol-lowering drug^[1]^[2] but was pulled due to cardiac side-effects. It also increases hepatic lipase which in turn improves utilization of triglycerides, improving apolipoprotein E cholesterol particles.^{[citation needed]}

References

This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.